A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

Unknown Phase 3 NCT03304054

Study Description

Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.

Study Details

Registry ID:: NCT03304054
Conditions:: Myasthenia Gravis, Generalized
Phase:: Phase 3
Target Enrollment:: 93 participants
Start Date:: April 18, 2018
Healthy Volunteers:: No

Study Locations (2 sites)

Univerity of Pennsylvania
Philadelphia, PennsylvaniaUnited States, United States
Cleveland Clinic
Cleveland, OhioUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.org.

View full study details and check eligibility →